Geriatric Conditions and Prescription of Vitamin K Antagonists vs. Direct Oral Anticoagulants Among Older Patients With Atrial Fibrillation: SAGE-AF by McManus, David D. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Population and Quantitative Health Sciences 
Publications Population and Quantitative Health Sciences 
2019-10-30 
Geriatric Conditions and Prescription of Vitamin K Antagonists vs. 
Direct Oral Anticoagulants Among Older Patients With Atrial 
Fibrillation: SAGE-AF 
David D. McManus 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/qhs_pp 
 Part of the Cardiology Commons, Cardiovascular Diseases Commons, Epidemiology Commons, 
Geriatrics Commons, Health Services Administration Commons, and the Therapeutics Commons 
Repository Citation 
McManus DD, Kiefe CI, Lessard DM, Marino F, Goldberg RJ, Gurwitz JH, Wang W, Barton BA. (2019). 
Geriatric Conditions and Prescription of Vitamin K Antagonists vs. Direct Oral Anticoagulants Among 
Older Patients With Atrial Fibrillation: SAGE-AF. Population and Quantitative Health Sciences Publications. 
https://doi.org/10.3389/fcvm.2019.00155. Retrieved from https://escholarship.umassmed.edu/qhs_pp/
1324 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Population and 
Quantitative Health Sciences Publications by an authorized administrator of eScholarship@UMMS. For more 
information, please contact Lisa.Palmer@umassmed.edu. 
ORIGINAL RESEARCH
published: 30 October 2019
doi: 10.3389/fcvm.2019.00155
Frontiers in Cardiovascular Medicine | www.frontiersin.org 1 October 2019 | Volume 6 | Article 155
Edited by:
Nathan D. Wong,
University of California, Irvine,
United States
Reviewed by:
Christoph Sinning,
Universitäres Herzzentrum Hamburg
GmbH (UHZ), Germany
Hack-Lyoung Kim,
SMG-SNU Boramae Medical Center,
South Korea
*Correspondence:
David D. McManus
david.mcmanus@umassmed.edu
Specialty section:
This article was submitted to
Cardiovascular Epidemiology and
Prevention,
a section of the journal
Frontiers in Cardiovascular Medicine
Received: 17 June 2019
Accepted: 11 October 2019
Published: 30 October 2019
Citation:
McManus DD, Kiefe C, Lessard D,
Waring ME, Parish D, Awad HH,
Marino F, Helm R, Sogade F,
Goldberg R, Hayward R, Gurwitz J,
Wang W, Mailhot T, Barton B and
Saczynski J (2019) Geriatric
Conditions and Prescription of Vitamin
K Antagonists vs. Direct Oral
Anticoagulants Among Older Patients
With Atrial Fibrillation: SAGE-AF.
Front. Cardiovasc. Med. 6:155.
doi: 10.3389/fcvm.2019.00155
Geriatric Conditions and Prescription
of Vitamin K Antagonists vs. Direct
Oral Anticoagulants Among Older
Patients With Atrial Fibrillation:
SAGE-AF
David D. McManus 1,2*, Catarina Kiefe 1, Darleen Lessard 1,2, Molly E. Waring 3,
David Parish 4, Hamza H. Awad 4, Francesca Marino 2, Robert Helm 5, Felix Sogade 6,
Robert Goldberg 1, Robert Hayward 7, Jerry Gurwitz 8, Weijia Wang 2, Tanya Mailhot 9,10,
Bruce Barton 1 and Jane Saczynski 9
1Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA,
United States, 2Cardiology Division, Department of Medicine, University of Massachusetts Medical School, Worcester, MA,
United States, 3Department of Allied Health Sciences, University of Connecticut, Mansfield, MA, United States, 4Department
of Community Medicine/Internal Medicine, Mercer University School of Medicine, Macon, GA, United States, 5Department of
Medicine, Boston University School of Medicine, Boston, MA, United States, 6Department of Medicine, Mercer University
School of Medicine, Macon, GA, United States, 7Department of Electrophysiology, Kaiser Permanente Santa Clara Medical
Center, Santa Clara, CA, United States, 8Division of Geriatric Medicine, University of Massachusetts Medical School,
Worcester, MA, United States, 9Department of Pharmacy and Health System Sciences, Northeastern University, Boston,
MA, United States, 10Montreal Heart Institute Research Center, Montreal, QC, Canada
Background: Geriatric conditions are common among patients with atrial fibrillation (AF)
and relate to complications of oral anticoagulation (OAC).
Objective: To examine the prevalence of geriatric conditions among older patients with
AF on OAC and relate type of OAC to geriatric conditions.
Methods: Participants had a diagnosis of AF, were aged ≥65 years, CHA2DS2VASC
≥ 2, and had no OAC contraindications. Participants completed a 6-component geriatric
assessment that included validated measures of frailty (CHS Frailty Scale), cognitive
function (MoCA), social support (MOS), depressive symptoms (PHQ9), vision, and
hearing. Type of OAC prescribed was documented in medical records.
Results: 86% of participants were prescribed an OAC. These participants were on
average aged 75.7 (SD: 7.1) years, 49% were women, two thirds were frail or pre-frail,
and 44% received a DOAC. DOAC users were younger, had lower CHA2DS2VASC
and HAS-BLED scores, and were less likely to be frail. In Massachusetts, pre-frailty
was associated with a significantly lower odds of DOAC vs. VKA use (OR = 0.64,
95%CI 0.45, 0.91). Pre-frailty (OR = 0.33, 95%CI 0.18–0.59) and social isolation
(OR = 0.38, 95%CI 0.14–0.99) were associated with lower odds of DOAC receipt
in patients aged 75 years or older. Social isolation was associated with higher
odds of DOAC use (OR = 2.13, 95%CI 1.05–4.29) in patients aged 65–74 years.
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Conclusions: Geriatric conditions were common and related to type of OAC
prescribed, differentially by age group. Research is needed to evaluate whether a geriatric
examination can be used clinically to better inform OAC decision-making in older patients
with AF.
Keywords: atrial fibrillation, anticoagulation, frailty, social isolation, older adults
INTRODUCTION
Stroke prevention is central to atrial fibrillation (AF) treatment,
and guidelines support use of oral anticoagulants (OAC) for
AF patients at elevated risk for stroke (1). Three out of four
AF patients aged 65 and older meet guideline criteria for OAC
treatment (2).
Historically, use of an OAC for stroke prevention in AF
meant use of a vitamin K antagonist (VKA). This treatment
often requires frequent testing and dosing changes, since
fluctuations in VKA response can result from diet, comorbid
diseases, genetic variations, and drug-drug interactions. Four
direct oral anticoagulants (DOACs) have been approved by
the FDA for stroke prevention in non-valvular AF. These
include: dabigatran, a direct thrombin inhibitor, and three factor
Xa inhibitors, rivaroxaban (3), apixaban, and edoxaban (4).
Recent AF management guidelines suggest that these agents be
considered as first-line therapy for AF (5).
Despite the inclusion of older patients in several clinical
trials comparing DOACs vs. VKA (6–8), many older patients
were excluded due to comorbid illnesses. Since advanced age
and common comorbidities may alter the pharmacokinetics of
DOACs, the decision to prescribe a VKA or DOAC in “real-
world” patients remains a conundrum. Although post-market
surveillance studies show similar outcomes among DOAC and
VKA-treated patients, few studies have examined differences
in factors related to aging that strongly impact treatment
outcomes (9). Conditions common in older patients, such as
cognitive impairment, frailty, and social isolation adversely
impact patient outcomes and are increasingly recognized as
important components of prescribing decision making (10–
17). In response to accumulating data that psychosocial factors
influence treatment outcomes in older patients, AHA/ACC
Guidelines for AF Management (1), as well as the AHA/ACC
guidelines for other cardiovascular conditions, such as AMI,
include consideration of CI, depression and social support in
patient management (18). Also, geriatrics-specific guidelines for
acute coronary care were developed by the AHA and ACC
in 2007 (19), further highlighting the increasing attention to
age-related factors in the management and outcomes of CVD.
Although several of these conditions have been examined for
their association with AC prescribing (20), whether type of
AC prescribed varies according to psychosocial and geriatric
conditions has not been examined.
Using data from the ongoing Systematic Assessment of
Geriatric Elements in Atrial Fibrillation (SAGE-AF) prospective
cohort study, we examined the characteristics of patients treated
with DOACs vs. VKAs in a “real-world” cohort of older patients
with AF. The objective of this study was to examine the
prevalence of geriatric conditions among older patients with AF
on OAC and relate type of OAC to geriatric conditions. We
hypothesized that the presence of geriatric conditions would
be associated with lower odds of receiving DOACs vs. VKAs.
Further, we hypothesized that geriatric conditions would have
different associations with prescribing patterns in younger vs.
older patients with AF.
MATERIALS AND METHODS
SAGE-AF is an ongoing study of AF, OAC treatment, and
relations between geriatric conditions and clinical outcomes
in adults aged 65 years and older. Consenting participants
completed a comprehensive baseline geriatric assessment, a
structured interview, and review of their medical records.
To be eligible for SAGE-AF, participants must have: (1)
been scheduled for an ambulatory care visit at a practice in
Massachusetts or Georgia, (2) had a history of AF documentation
on an electrocardiogram, Holter monitor, clinic note, or hospital
record, and (3) had a CHA2DS2VASC risk score ≥2 (indication
for OAC) (2). Participants were not eligible for enrollment
if they had documentation of an OAC contraindication, had
an indication for OAC other than AF, did not demonstrate
capacity to provide informed consent (21), did not speak English,
had a planned invasive procedure with possible uncontrollable
bleeding, were pregnant, were in prison, or were unwilling or
unable to participate in follow-up visits at their study sites.
All participants received an invitation to participate before
their clinic visit. All participants provided written consent, and
all study protocols were approved by the respective Institutional
Review Boards. Between June 2016 and August 2018, 1,244
patients were enrolled.
All SAGE-AF participants had a medical history and
physical examination performed in the context of their routine
care. Trained study staff abstracted all demographic, clinical,
treatment, and laboratory characteristics from participants’
medical records. All participants underwent a comprehensive
interview that included a 6-component geriatric assessment using
validated measures of frailty, cognitive function, social support,
depressive symptoms, vision, and hearing. Frailty was assessed
using the Cardiovascular Health Survey (CHS) frailty scale (22),
a biological model of frailty based on five components: weight
loss/shrinking; exhaustion; low physical activity (Minnesota
Leisure Time Activity questionnaire) (23); slow gait speed (15-
foot timed walk); and weakness (grip strength). Each element
receives a single point and the frailty index ranges from 0 to 5.
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Based on the CHS scoring guidelines (22), a participant is frail if 3
or more criteria are present, pre-frail if 1 or 2 criteria are present,
and not frail if 0 criteria are present.
To assess cognition, participants completed the Montreal
Cognitive Assessment Battery (MoCA), a 30-item screening tool
designed to assist care healthcare providers in detecting mild
cognitive impairment. A cut-point of 23 was used to classify
cognitive impairment (24). The 6-item Social Network Scale was
used to assess the participants’ social networks and a cut-point
of <12 was used to define social isolation (25). This measure of
social isolation reflects social connectedness; whether a person
has friends or family members to talk to about important issues
or to call when they need help. Social isolation is linked to higher
rates of disability, poorer recovery from illness and death (26–
28). The 9-item Patient Health Questionnaire (PHQ-9) was used
to assess depressive symptoms with a score of five used as a cut-
point for depressive symptoms (29). Patients self-report vision
and hearing impairments (30, 31).
STATISTICAL ANALYSIS
We compared the characteristics of SAGE-AF participants who
received OAC according to type of OAC (DOAC vs. VKA)
using analysis of variance for continuous variables and chi
square tests for categorical variables. We examined which
geriatric elements (independent variables: cognitive function,
frailty, social isolation, vision impairment, hearing impairment,
depression) were associated with OAC treatment type using
adjusted logistic regression analysis. In these analyses, we
adjusted for each geriatric element and then additionally for
clinical and demographic factors identified from univariate
analyses as being associated with treatment type at the p < 0.15
level. Differences in the clinical and treatment characteristics
were noted between participants from Massachusetts and
Georgia. As such, we conducted stratified regression analyses by
study site and adjusted for factors associated with OAC type. We
also stratified our regression analyses by age (65–74 years vs.≥75
years) since we were interested in whether geriatric conditions
influenced OAC prescription choice differently among older and
younger participants.
RESULTS
86% of the 1244 SAGE-AF participants were prescribed an
OAC. Of the participants prescribed an OAC, we excluded
15 participants missing data on one or more of the variables
included in the analysis, resulting in an analytic sample of 1,064
older patients with AF prescribed an OAC.
Of these participants, 44% were prescribed a DOAC and 56%
were prescribed VKA. Among those prescribed a DOAC, the
majority received apixaban (n= 238) and rivaroxaban (n= 184),
with a minority of participants receiving dabigatran (n = 40) or
edoxaban (n= 4). There was a high burden of cardiovascular and
non-cardiovascular comorbidities, including prior bleeding and
geriatric conditions (Table 1). Women comprised about half of
TABLE 1 | Characteristics of older adults with atrial fibrillation on oral
anticoagulation, according to type of oral anticoagulation: SAGE-AF, 2016–2018.
Characteristic Direct oral
anticoagulant
(n = 466)
VKA
(n = 598)
p-value
DEMOGRAPHIC CHARACTERISTICS
Age
65–74 years 251 (53.9) 268 (44.8) <0.001
75–84 years 178 (38.2) 223 (37.3)
85 years and older 37 (7.9) 107 (17.9)
Female 228 (48.9) 297 (49.7) 0.81
Race/Ethnicity
White 380 (81.6) 522 (87.3) <0.01
Non-White 86 (18.5) 76 (12.7)
Marital statusa
Married or living as married 266 (57.1) 327 (54.7) 0.73
Not Married 193 (41.4) 261 (43.7)
Educationb
High school/GED or less 45 (9.7) 45 (7.5) 0.22
Some college 209 (44.9) 310 (51.8)
College graduate 75 (16.1) 83 (13.9)
Graduate degree 130 (27.9) 150 (25.1)
Household incomec
>=50,000 208 (52.0) 224 (46.0) 0.08
Insurance statusd
Commercial/HMO/PPO 56 (12.0) 128 (21.4) <0.01
Medicare 350 (75.1) 422 (70.6)
Other 59 (12.7) 46 (7.7)
CLINICAL CHARACTERISTICS
AF type
Paroxysmal 298 (64.0) 302 (50.5) <0.001
Persistent 118 (25.3) 179 (29.9)
Permanent 19 (4.1) 50 (8.4)
Unknown 31 (6.7) 67 (11.2)
CHA2DS2VASC score (M, SD) 4.3 (1.6) 4.7 (1.6) <0.01
HAS-BLED score (M, SD) 2.8 (1.0) 3.0 (1.0) <0.05
AFEQT score (M, SD) 78.2 (18.9) 80.5 (16.9) <0.05
Botherede by ≥1 AF symptom
in the past 4 weeks
61 (13.2) 55 (9.2) <0.05
Medical history
Acute myocardial infarction 89 (19.1) 123 (20.6) 0.55
Alcohol abuse/dependency 165 (35.4) 168 (28.1) <0.05
Anemia 122 (26.2) 212 (35.5) <0.01
Bleeding 97 (20.8) 112 (18.7) 0.4
Chronic kidney disease 115 (24.7) 195 (32.6) <0.01
Chronic lung disease 123 (26.4) 145 (24.3) 0.42
Diabetes 140 (30.0) 166 (27.8) 0.41
Heart failure 159 (34.1) 250 (41.8) <0.05
Hyperlipidemia 354 (76.0) 495 (82.8) <0.01
Hypertension 415 (89.1) 551 (92.1) 0.08
Implantable cardiac device 163 (35.0) 203 (34.0) 0.73
Peripheral vascular disease 57 (12.2) 93 (15.6) 0.12
(Continued)
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TABLE 1 | Continued
Characteristic Direct oral
anticoagulant
(n = 466)
VKA
(n = 598)
p-value
Stroke 40 (8.6) 68 (11.4) 0.13
Creatinine (mg/dL) M (SD) 1.05 (0.37) 1.15 (0.65) <0.05
Hemoglobin (g/dL) M (SD) 13.1 (1.9) 13.1 (1.8) 0.96
TREATMENT CHARACTERISTICS
Aspirin 104 (22.3) 204 (34.1) <0.001
Clopidogrel 30 (6.4) 25 (4.2) 0.07
OVERALL TREATMENT SATISFACTION
Extremely satisfied 203 (43.8) 286 (48.0) 0.41
Very satisfied 147 (31.7) 187 (31.4)
Somewhat satisfied 61 (13.2) 64 (10.7)
Satisfied or less than satisfied 53 (11.4) 59 (9.9)
PSYCHOSOCIAL CHARACTERISTICS
Fall in past 6 months 91 (19.5) 143 (23.9) 0.09
Anxietyf 115 (24.7) 137 (22.9) 0.50
Living Alone 128 (27.5) 167 (27.9) 0.87
Independence (IADLs) 6.8 (0.9) 6.6 (1.1) <0.05
Confident in physician interactionsg 302 (66.8) 374 (64.3) 0.39
Practice type
Cardiologist 139 (29.8) 349 (58.4) <0.001
EP 319 (68.5) 233 (39.0)
Internist 8 (1.7) 16 (2.7)
an = 17 missing Marital Status.
bn = 17 missing Education.
cn = 177 missing household income.
dn = 3 missing Insurance Status.
equite/extremely/very bothered with symptoms.
fanxiety GAD7<=5.
gdefined based on a PEPPI score of >45.
the study sample, 85% were white, two-thirds were frail or pre-
frail, and 22% had suffered a fall in the last 6 months. Differences
in the overall proportion of DOAC treated participants and
factors associated with type of OAC prescribed were noted in
Massachusetts vs. Georgia (Supplemental Table 1).
Geriatric conditions, including frailty, depression, cognitive
impairment, social isolation, and visual and hearing impairments
were common (Table 1, Figure 1). Given the high rate of
cardiovascular comorbidity, study participants were at high risk
for thromboembolic, and bleeding complications based on their
CHA2DS2VASC and HAS-BLED risk scores. Slightly more than
three quarters (78%) of study participants reported being satisfied
or very satisfied with their overall treatment.
In comparison to participants receiving VKA, participants
treated with DOACs were, on average, younger, and had lower
average stroke and bleeding risk scores (Table 1). Notably,
participants treated with DOACs were more likely to have
paroxysmal AF, have had a symptomatic episode in the last 4
weeks, have seen a cardiologist or cardiac electrophysiologist,
and have reported lower OAC burden and higher disease-specific
quality of life (32). Finally, participants receiving DOACs were
less likely to be frail or pre-frail and had greater independence
in activities of daily living but were more likely to report
social isolation.
Among participants enrolled in Massachusetts, frail, pre-frail,
and cognitively impaired status were associated with 40, 46,
and 35% lower odds, respectively, of being treated with DOAC
(Table 2). After adjustment for stroke and bleeding risk scores
as well as other factors associated with type of OAC, pre-frail
status was associated with a significantly reduced odds of being
prescribed a DOAC (OR = 0.64, 95% CI 0.45, 0.91; Table 2).
When we stratified our analyses by age, pre-frail status, and
social isolation were associated with a more than 60% lower
odds of DOAC-receipt in older (>75 years) participants enrolled
in Massachusetts (Table 3). In contrast, low social isolation was
associated with an approximately 2-fold higher rate of DOAC
receipt among younger (65–74 years) participants enrolled in
Massachusetts (Table 3). The sample size in Georgia was not
large enough to examine these associations among patients
in Georgia.
DISCUSSION
Over 80% of SAGE-AF participants were prescribed an OAC,
a rate higher than has been reported in older cohorts but
consistent with more recent data (33). This higher rate may also
be explained by differences in the eligibility criteria used by our
study, which required that participants not have active bleeding
or other contraindications to OAC.
Although an increasing number of patients with AF are
prescribed DOACs, VKAs are frequently used for stroke
prevention (34). VKAs place a high burden on older patients,
with dietary and lifestyle restrictions, frequent lab monitoring,
and frequent dosage adjustments. We observed that 44% of
anticoagulated study participants were treated with DOACs,
a rate lower than has been reported in Europe and some
specialized US centers (33), but slightly higher than what was
reported by the IMS Health National Disease and Therapeutic
Index (38%) (35). Consistent with national prescription rates,
we observed that apixaban and rivaroxaban were the most
commonly prescribed DOACs. Study region and prescriber type
(cardiac electrophysiologist vs. other) were associated with type
of OAC used for AF (Table 1).
Clinical trials and meta-analyses have suggested that DOACs
may be safer than VKA in older trial participants (36, 37);
however, many older patients were excluded from these studies
based on commonly occurring comorbidities. The decision of
VKA vs. DOACs in “real-world” patients remains a conundrum,
since advanced age, and common comorbidities (e.g., renal
impairment) increase the risk of adverse events from both agents
(38). Moreover, in contrast to VKA, reversal agents for DOACs
were not widely available during the study period, an important
consideration formany providers since older patients with AF are
at high risk for falls and traumatic bleeding (39).
Prior studies have shown that geriatric conditions, including
cognitive impairment, frailty, and depression, are associated
with a higher odds of not being prescribed OAC despite
being eligible (40, 41); however, few studies have examined
relations between geriatric conditions and type of OAC selected
(42, 43). We hypothesized that older, frailer participants
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FIGURE 1 | Number of older adults with atrial fibrillation on oral anticoagulation, according to type of oral anticoagulation, and frailty category: SAGE-AF, 2016-2018.
Not frail, 0 impairments; Pre-frail, 1–2 impairments; Frail, 3–5 impairments (impairments include unintentional weight loss, weakness, exhaustion, slow gait, low
physical activity) as defined by the CHS Frailty Scale (22).
TABLE 2 | Receipt of DOAC vs. VKA by geriatric element status among older adults with atrial fibrillation treated with oral anticoagulation enrolled in Massachusetts
(n = 818): SAGE-AF, 2016–2018.
Odds of receiving a DOAC
Geriatric elements Received
DOAC, N (%)
p-value M1 unadjusted OR
(95% CI)
p-value M2 adjusted OR
(95% CI)
p-value
Frailty
Frail 29 (10.4) <0.01 0.60 (0.37, 0.99) 0.41 0.88 (0.48, 1.61) 0.74
<0.05Pre-frail 126 (45.3) 0.54 (0.39, 0.74) <0.05 0.64 (0.45, 0.91)
Not frail 123 (44.2) (Reference) (Reference)
Cognitive impairment 89 (32.0) <0.05 0.65 (0.48, 0.89) <0.01 0.95 (0.67, 1.34) 0.76
Social isolation 28 (10.1) 0.97 1.01 (0.62, 1.63) 0.97 1.11 (0.66, 1.86) 0.70
Visual impairment 82 (29.5) 0.46 0.89 (0.65, 1.22) 0.46 1.02 (0.72, 1.44) 0.91
Hearing impairment 103 (37.1) 0.57 0.92 (0.68, 1.24) 0.57 1.03 (0.75, 1.43) 0.85
Depression 65 (23.4) 0.17 0.79 (0.57, 1.11) 0.17 0.79 (0.53, 1.19) 0.27
M1, Unadjusted logistic regression model for each geriatric element (main independent variables): frailty, cognitive impairment, social isolation, sensory impairments (visual and hearing),
depression; M2, M1 additionally adjusted for risk scores (CHA2DS2VASC, HAS-BLED), education, insurance, AF type, AFEQT score, hyperlipidemia, alcohol abuse, anemia, CKD,
aspirin use, fall in past 6 months, IADL, provider type, frailty, and cognitive impairment. Age was accounted for via CHA2DS2VASC.
affected by a greater burden of geriatric conditions would be
prescribed VKA, since these conditions are associated with renal
impairment, polypharmacy, and other age-related factors that
affect DOAC treatment.
Our finding that pre-frailty status (1–2 impairments) was
associated with lower odds of being treated with a DOAC
supports this hypothesis. Although the association between
frailty status (more than 2 impairments) and greater odds of
DOAC did not achieve statistical significance, the direction
of the association was the same as pre-frailty (Table 2). We
suspect the lack of statistical significance may have related to
the smaller number of participants in the frail (vs. pre-frail)
category. Furthermore, we observed a similar but statistically
more robust finding among participants aged 75 years and
older, but not among younger participants (65–74 years old).
This suggests that the impact of geriatric conditions on OAC
prescribing may be greatest among individuals older than
75 years of age. Furthermore, social isolation was associated
with a 2-fold higher rate of DOAC use among younger
patients. This relationship may be explained by the benefits
of social support for handling the burden of monitoring and
clinical follow-up required to manage VKA. However, among
the oldest participants in our cohort, social isolation was
associated with 62% lower odds of DOAC receipt. This counter-
intuitive finding may be explained by AF patients or their
providers perceiving frequent OAC clinic nurse evaluations
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TABLE 3 | Receipt of DOAC vs. VKA by geriatric element status among older adults with atrial fibrillation treated with oral anticoagulant enrolled in Massachusetts, further
stratified by age (75-years cutoff): SAGE-AF, 2016–2018.
Geriatric elements DOAC N (%) p-value M1 unadjusted OR (95% CI) p-value M2 adjusted OR (95% CI) p-value
<75 (N = 406)
Frailty
Frail 12 (7.4) 0.60 (0.28, 1.26) 0.27 0.84 (0.35, 2.01) 0.73
Pre-Frail 72 (44.4) 0.30 0.80 (0.53, 1.21) 0.90 0.94 (0.59, 1.50) 0.93
Not frail 78 (48.2) (Reference) (Reference)
Cognitive impairment 45 (27.8) 0.84 0.96 (0.62, 1.49) 0.84 1.39 (0.84, 2.31) 0.20
Social isolation 22 (13.6) 0.11 1.67 (0.89, 3.15) 0.11 2.13 (1.05, 4.29) <0.05
Impaired vision 52 (32.1) 0.75 0.93 (0.61, 1.43) 0.75 1.20 (0.75, 1.93) 0.45
Impaired hearing 51 (31.5) 0.22 1.32 (0.85, 2.05) 0.21 1.44 (0.89, 2.34) 0.14
Depression 37 (22.8) 0.11 0.69 (0.44, 1.10) 0.12 0.71 (0.40, 1.26) 0.24
>=75 (N = 412)
Frailty
Frail 17 (14.7) <0.01 0.63 (0.32, 1.25) 0.99 0.56 (0.23, 1.41) 0.97
Pre-frail 54 (46.6) 0.39 (0.24, 0.63) <0.01 0.33 (0.18, 0.59) <0.01
Not frail 45 (38.8) (Reference) (Reference)
Cognitive Impairment 44 (37.9) <0.01 0.55 (0.35, 0.85) <0.01 0.67 (0.40, 1.11) 0.12
Social isolation 6 (5.2) <0.05 0.44 (0.18, 1.07) 0.07 0.38 (0.14, 0.99) <0.05
Impaired vision 30 (25.9) 0.32 0.79 (0.49, 1.27) 0.33 0.85 (0.49, 1.48) 0.56
Impaired hearing 52 (44.8) 0.34 0.81 (0.53, 1.25) 0.35 0.84 (0.52, 1.35) 0.47
Depression 28 (24.1) 0.69 0.91 (0.55, 1.49) 0.69 0.94 (0.51, 1.75) 0.85
M1, Unadjusted logistic regression model for each geriatric element individually (main independent variables): frailty, cognitive impairment, social isolation, sensory impairments (visual
and hearing), depression; M2, M1 additionally adjusted for risk scores (CHA2DS2VASC, HAS-BLED), education, insurance, atrial fibrillation type, AFEQT score, hyperlipidemia, alcohol
abuse, anemia, chronic kidney disease, aspirin use, fall in past 6 months, IADL, provider type, frailty, and cognitive impairment.
and/or laboratory monitoring as a potential benefit for socially
isolated elders.
Our findings have important potential clinical implications.
Since AF patients in the pre-frail category were more likely
to receive VKA, previously published secondary data analyses
suggesting that DOACs have a favorable safety profile may
suffer from unmeasured confounding (43). Second, patients
receiving OAC had high rates of geriatric conditions, placing
these individuals at elevated risk for OAC complications. In
contrast to patients on VKA, patients receiving DOACs for AF
are infrequently followed by anticoagulation clinics, nor do they
systematically receive OAC education. Anticoagulation clinics
support providers by helping to manage AF patients and perform
routine drug safety and laboratory monitoring; however, these
critical care pathways are not routinely made available to DOAC-
treated patients.
Our findings also suggest that social isolation may influence
OAC prescribing patterns and that the role of social isolationmay
differ among younger and older patients. Future studies should
explore whether or how physicians and patients include the
patient’s social circumstances into conversations about treatment
decision-making. Efforts to integrate support of DOAC-treated
patients into traditional OAC clinics appear well-founded.
Studies are needed to demonstrate that such supportive care
improves patient outcomes.
The strengths of our study include the geographic diversity
of the study cohort, inclusion of older AF patients with a high
degree of comorbidity, and high rates of OAC use. Furthermore,
the comprehensive assessment of factors associated with aging
used validated and publicly available instruments that can be
utilized in an office visit. Study limitations include the cross-
sectional nature of our analysis. Information was not available
about each participant’s history or duration of exposure to OAC,
and participants may have recently switched from DOAC to
VKA or VKA to DOAC prior to study enrollment. However,
prior studies show low overall rates of switching after initial
OAC prescription, particularly among DOAC-treated patients
(42, 44). Importantly, we had limited power to evaluate the
associations between geriatric elements and use of DOACs
among participants in Georgia, and thus cannot conclude
whether the observed point estimates for these associations
are statistically significant. Further research in other large,
diverse samples are needed to validate our findings, especially
considering the regional variation in OAC prescribing observed
in our study.
CONCLUSIONS
In a well-characterized, diverse sample of older patients with
AF treated with OAC, we observed that the rates of readily
assessed geriatric conditions were high and that several geriatric
conditions, including pre-frailty and social isolation, were
associated with a lower likelihood of receiving a DOAC. In
light of guideline changes favoring DOACs over VKA for safety
and effectiveness (5), additional efforts to provide tailored OAC
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education and support to frail and socially isolated patients may
be necessary.
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